:
I call this meeting to order.
Welcome to meeting number 146 of the House of Commons Standing Committee on Health.
In accordance with our routine motion, I'm informing the committee that all remote participants, with the exception of Dr. Hanley, have completed the required connection tests in advance of the meeting. We will have Dr. Hanley's issues resolved before we call on him to speak.
We're going to skip over the budget.
Pursuant to Standing Order 108(2), the committee is commencing its study of the subject matter of the supplementary estimates (B), 2024-25.
I'd like to welcome the panel of witnesses joining us today.
We have the Honourable Mark Holland, Minister of Health. He has a team of officials accompanying him. From the Canadian Food Inspection Agency, we have Diane Allan, associate vice-president, policy and programs. From the Canadian Institutes of Health Research, we have Dr. Tammy Clifford, acting president. From the Department of Health, we have Eric Costen, associate deputy minister. From the Public Health Agency of Canada, we have Heather Jeffrey, president; Dr. Kerry Robinson, acting vice-president, infectious disease and vaccination programs branch; and Linsey Hollett, assistant deputy minister, regulatory operations and enforcement branch.
Thank you all for being here, albeit somewhat delayed.
You're very familiar with how things work here, so I'm just going to hand it over to you, Minister. Welcome to the committee. You have up to five minutes for your opening statement.
:
Thank you very much, Mr. Chair.
Yes, I was hoping...we had made a request to come here before the supplementary estimates. Nonetheless, it's a very important conversation to have. I thank you, Mr. Chair, for having us here today.
You referenced a number of officials. I want to take a moment to thank them for their extraordinary work on behalf of the country. It is my very deep and great privilege to have an opportunity to work with them as they work to serve Canadians.
I'm going to talk at a high level, if I can. We're in a moment of incredible consequence for health care in Canada, and it is wonderful. I've had an opportunity over the last couple of months, as I do all the time, really, to go and talk with stakeholders, particularly about the optimism within the health sector about the transformation that's possible.
I just came back from Alberta on Friday, where I had a conversation with Adriana LaGrange about the possibility of working together, finding solutions and being able to talk about common language. We have a lot of differences, but one of the things, when you look at the transformation that must occur in our health system, is that there are a lot of areas of commonality that are really worth focusing on.
About 70% of chronic diseases and illnesses can be prevented. Most of what fills our hospital rooms and hospital beds doesn't need to be there. Having an effective response to prevention not only makes sense as a matter of health outcomes, but fundamentally makes sense economically. It's something that can unite us, whether or not we are thinking about social justice and health outcomes or we're thinking about productivity.
I have to say that around the federal-provincial table, the positivity and the efforts to set aside partisanship and find common ground have been deeply heartening. I had a conversation with Jeremy Cockrill, who's the new health minister in Saskatchewan, about that, which was very positive. A conversation with Michelle Thompson was very positive.
I look forward to talking to the committee in that spirit and to take your questions in that spirit, because we've been able to do some really important things.
Let me start with dental. At the most recent update, 93% of providers are participating. Now, you might recall that some folks said we weren't going to have anybody sign up, so 93% is pretty fantastic. Manitoba is leading the pack now, with nearly 100%. In fact, we have to redefine 100%, because people who we didn't even know were providers have come forward.
In terms of the number of people who have received care, we're at 1.25 million, and that's in just over seven months. In a year, three million registered, so I'm very excited for these next cohorts.
I mentioned dental to start because it's such an important area of both primary care and prevention. It's also an example of Parliament working together in the spirit of collaboration. I see Peter Julian, and I want to recognize in the work that was done. It's difficult to find common ground and ask constructive questions about how we can help Canadians, but that's what they expect us to do in a minority Parliament.
Now we're moving forward on the pharmacare agreements, which are also the product of co-operation in this chamber. Those agreements are going to apply to diabetes medication and devices, as well as contraceptives.
It was wonderful to stand at a podium on drugs for rare diseases with Adriana LaGrange as she made the commitment that Alberta is ready to move toward signing it. I very much believe that all of these agreements can be signed over the coming time.
One of the areas I'm really hoping we can focus on today, Mr. Chair, is Bill . I'm not aware of anybody who's against the connected care legislation. This is legislation that will absolutely save lives.
If you talk to Teri Price about the experience of her brother Greg and the problem with fax machines and data not being transferred and a system that doesn't have interoperability, you'll hear that these problems place lives at risk, block pathways to care and are some of the greatest frustrations for physicians.
I understand that there are a lot of things going on and there are a lot of concerns, but here's an example of how we can come together. There are lots of things we can disagree on, but on this one, I'm aware of no province and no territory that's opposed and I'm aware of no political party that's opposed, so I would ask for parliamentarians' assistance to pass this bill. It will save lives and improve our health system. I'm not aware of anybody who's opposed to it, so hopefully, we can spend some time on that.
I would say in closing, Mr. Chair, that I appreciate these conversations. I hope I'm afforded 20 seconds of context. I love playing Jeopardy!, but this is an important conversation that we need to have on the future of health care in this country, and it is certainly deserving of more than staccato two-second questions.
I look forward to the opportunity to illuminate, and to have a conversation on, the ways we can work together to the betterment of our health system.
The previous budget, budget 2024, had provided dollars for us to launch the first deals. Obviously, we're well into the year, so when these deals are signed, they'll be prorated.
I want to thank you for your advocacy in the area of diabetes. It's been so important. This country spends about $30 billion a year managing diabetes, and that's just in direct health costs; it doesn't account for lost productivity and the cost to business in this country.
The biggest challenge within that is folks not being able to access their medicine. I can tell you that it's devastating to talk to doctors who have patients in front of them who can't follow through on their treatment regime because they don't have money for their medicine. It is fundamentally essential that everybody be connected to the medicine that they need.
This is a really important step forward, and I think it's a great example of what Parliament can accomplish when we focus on shared objectives.
We're ready to sign those deals very soon. There's obviously a lot that goes into them. As you would have seen from the memorandum of understanding with British Columbia, there's an opportunity to go further than what Parliament envisioned. In British Columbia, we had the drugs involved in hormone replacement therapy for women added to the list, which is deeply exciting. I hope to have other exciting things to be able to talk about as we sign these agreements in the coming days.
:
That's a great question.
If you look at Europe right now, you see that Europe is working collaboratively to eliminate any barriers for interoperability in its system and to have data that flows as freely as rivers. With the advent of AI and new technology, if we have a fragmented data system with data that's locked up in places where we can't get hold of it, we're going to be running around in circles. We'll miss an opportunity for prevention that's absolutely outstanding.
I'll talk about our good friend and former colleague, Arnold Chan. Arnold was very close to all of us. He was somebody who reached across the aisle and loved this Parliament very deeply. He had a genetic form of cancer. It didn't get caught early enough, but he was able to then tell his brother to get screened. His brother found out that he had the same cancer. It saved his brother's life.
In an interconnected data system, once we can sequence the human genome in the next couple of years and have that available to people, being able to tell patients that they're genetically at risk for particular diseases is absolutely so powerful. This is what Bill can unlock. It would be a wonderful legacy to think of Arnold and what this portends by passing that legislation. I hope that we do it.
It also means incredible things for reducing administrative burden. Maybe I'll talk about that for a second.
You know how frustrating it is to send the same form three or four times, to have information get lost in paper and to not have the ability to send a prescription digitally. We have tools like AI scribes, which can do some of the most menial work around taking notes and take it off a doctor's shoulders. If we can apply that across the system and if we could put that in place, that's equivalent to 1,000 doctors overnight. We can't do that if we don't pass Bill .
A lot of times, data doesn't sound sexy, but the power of data to transform our health system is outstanding. Europe is doing it. We shouldn't waste a second. We have to do it as well. I hope that we can pass it in this Parliament.
:
Come on, I want to have some speaking time too, Mr. Chair.
How do you explain the fact that requests denied by your plan are accepted when they are submitted to private sector companies?
Sun Life is not even able to tell denturists why requests are being denied.
This is not a technical issue, Minister. It's an issue of competence in the analysis of requests.
How do you explain that discrepancy?
You offer a private program that leads people to believe that they will have access to services, but then they have to pay their bills. There is also a backlog of unresolved files. The program does not work. We can pat ourselves on the back all we want, but there is a problem.
How and when are you going to fix it?
:
I'll continue with the officials later.
[English]
I'm going to switch to English now.
The reality is that I'm a little surprised by the questions from the official opposition. There is no doubt that this is one of the most popular new federal programs in decades.
Just from a count and from what you've said, Minister, 3,700 Canadians on average in each and every Conservative riding in the country, including Mr. Doherty's and Dr. Ellis's, have received dental care. What the NDP has fought for in terms of pharmacare means about 17,000 of their constituents. It's a bit strange to me to see Conservatives threatening to kill programs that help thousands of their constituents. I don't understand that.
That's a comment I wanted to express.
In terms of where dental care goes from now, I stress that it's really important to extend it beyond seniors, children and people with disabilities to others who meet the family income threshold.
When can we expect the government to look at coverage for seniors who have existing dental programs that are very poor? That's a question that comes up from my constituents regularly.
Also, when do you expect to address the issue of Canadians who are denied dental care because they have a non-resident spouse? That's an issue that has come up as well.
In terms of the average response time for pre-approval for dentures, I would like to know what the existing response time is in addition to the problem that Mr. Thériault raised.
Thank you.
In the first order, three million people have signed up, and already one and a quarter million people are getting care. The demand is absolutely massive, and I think we're going to be able to demonstrate in evidence not only what that means to people's dignity but also what that means in terms of better health outcomes and, frankly, saving money because they don't wind up in emergency rooms with much more serious cases.
We do have a lot of people left to go. Almost every single senior who's eligible has signed up for this program, but you're right about the additional cohorts. What I always said was that this was going to be a very big lift. Pre-authorization is extremely complex, which is one of the reasons I said that we didn't want to advance the new cohorts until we got the pre-authorization piece right. This was anticipated. Working through these issues, I think, is critical.
It's less a question of how long it's taking. What's happening with the rejected claims is that either information isn't being attached or there's a misunderstanding of what's required.
If you can imagine, this is very expensive and we have to be able to demonstrate that there's integrity built around the system. By its nature, it's not just automatically approved, because it's quite complicated work. It's not that it's taking a lot of time; it's that there were pieces missing, and people not understanding what they need to attach is the problem.
That's why I think we can work through that pretty carefully—
It came out of the Senate on October 5, so there are a lot of details to chew through, but very early in the new year I expect to see the first agreement signed. I think you can look at the MOU with B.C. to get a flavour for what those would look like. They use the existing infrastructure of provinces, so I think we can get medicine to people very quickly.
As I said, I'm deeply encouraged that a jurisdiction like Alberta.... As I said, last week I was in Alberta announcing our plan for drugs for rare diseases. Alberta was saying that it's very interested in signing this and finding a solution. Adriana, their health minister, believes it can be done. I think if we can do it in Alberta, we can do it everywhere, and I believe we will.
As the first order, for any person—and I know you would share it in my heart, and you would share it in yours—who loses a family member, it is devastating. We need to use science, data and evidence to provide solutions, not emotions and not fake policies. We have to provide real answers, and that's what we will offer—true science-based, evidence-based decisions to save people's lives.
If you take scurvy—and I'll just finish on this, because you want to talk about facts—somebody who's so food insecure that they have scurvy doesn't drive around in a car. They don't pay the carbon tax, but you would take away their cheque. You would take away the benefit they get every single quarter that helps them pay for groceries. That's what you would do. You would leave them less secure and in a more vulnerable position.
Sir, those are the facts.
:
Okay, very good. Thank you so much, and I apologize to the committee for my technical problems.
I do want to note that I want to reserve the final two minutes of my five minutes for Mr. Morrice to ask an important question, so please, Mr. Chair, assist me in that.
Thank you, Minister and officials, for appearing. I did want to ask a couple of questions.
First, in the supplementary estimates, $53 million is devoted to increased support for scholarships and fellowship awards. I hear a lot about the need for more investment in health research, particularly in postgraduate research. I wonder if you'd like to speak briefly to the importance of that from your point of view, Minister.
Of course, we know research is absolutely fundamental to health transformation. It is the pathway to understanding how we deal with the problems that face us in a complicated world. There isn't a health system that isn't facing these challenges in the world.
I was so happy—as I know you were, Mr. Hanley—that in budget 2024 we responded to the Bouchard report's recommendations to make sure that we have the appropriate supports for postgraduate and graduate students be able to study here and to be able to call Canada home for the research they do.
Research leads to miracles. It is very much the responsibility of.... It really is thanks to research that we have been able to make the kind of progress we have. I'll just give you one example. We talked earlier about diabetes. Canada is perhaps three to five years away from being the country that solves type 1 diabetes, and it is because of the extraordinary researchers in this country. Making sure that the next generation of researchers has the support they need is critical. Money that was in the supplementary estimates to further those goals is critical, not just to keep researchers here so that the science is here and the jobs are here, but also so that the solutions of tomorrow that end the diseases of today are driven and done here in Canada.
:
Thank you, Dr. Hanley, and thank you, Chair.
Mr. Holland, you might remember that we spoke in Parliament earlier this year about a constituent of mine, Noor Ayesha. She'd received a terminal diagnosis of bile duct cancer just after giving birth to her daughter back in February 2023. She and her family and donors on GoFundMe had to raise money to fund a drug that had been approved by Health Canada but not recommended by Canada's Drug Agency. It's a drug that cost $15,000 a month, and it extended her life. Sadly, Noor passed away about a month ago.
The glimmer of hope is that the CDA is now in the midst of reconsidering its decision for a possible recommendation as I and, more importantly, her own oncologist and other doctors had been calling for.
I'm sure you also know that the Canadian Cancer Society released a report this week that shows that the average cancer patient in Canada is grappling with nearly $33,000 in costs over the course of their lifetime. I'm sure that saddens you in the same way it does me, and so I wonder what you can do, or even commit to, in terms of streamlining approvals and funding decisions to speed up access to cancer drugs.
:
Thank you, Mr. Morrice. I want to thank you for your advocacy on this, and to say that Noor's case is deeply tragic and is something that lights a fire in us to do everything that we can for action.
I have two quick points. Health Canada, once it approves that a drug is going to be eligible for public reimbursement, it's then up to the provinces to make the decision about whether or not it is publicly reimbursed—I'm sorry: Health Canada approves it, and then the provinces decide if it's eligible for reimbursement.
The arm's-length decision of Canada's Drug Agency is important. Obviously, we want those science-based decisions to not be influenced by politics, but the agreements that we're signing for drugs for rare diseases are so critical. I was so excited to sign the third one in Alberta, because it's a collective commitment to expand our action on drugs for rare diseases and to show a coordinated approach to these diseases. To take cancer as an example, there are costs. We have to do a much better job.
It's pretty incredible, in this country, when you walk into the cancer ward of a hospital. I talked to a doctor there. When she started 30 years ago, the survival rate was only 30%: Today it's 90%. When I talked to those patients.... In fact, I talked to one patient about the experience of an American family member, who was wiped out entirely. They lost everything because of a cancer diagnosis. That's not our case here.
It's still too expensive. We have to do better. However, I think that seeing people where they are and recognizing the urgency of the devastating thing this does to families.... Look, it's bad enough to get a diagnosis, but then to wonder how the heck you're going to pay for your medication is just fundamentally unfair, so we have to go as fast and as far as we can.
Thank you for the question.
:
Minister, you're talking about two weeks of failure in your dental care plan, but that's not true. On November 1, people were waiting for your service and thought they would have access to it. However, today is December 12. When you do the math, you see that the delay is one month and 11 days.
Your plan seems to have been written on the back of a napkin or envelope. That's actually what we were challenging, not the principle of access to dental care along with greater coverage.
However, your plan has been poorly explained, and people think that dental care is free. When people go to the dentist, they realize that they have to pay the difference between the dentist's rate and the fees covered by the plan. From what I hear from various constituency offices, the fee schedule for dentists has practically doubled.
Why didn't you take the time to sit down with the dentists to negotiate a fee schedule? Right now, people find themselves in a humiliating position when they don't have the money to pay for their care. They are told that, ultimately, the care isn't free and that they have to pay the difference.
How are you going to manage that? People are using the government portion as a gift card.
:
Look, it takes everybody moving in the same direction. It's not enough that the federal government does its part. Obviously, hospitals and health systems are actually managed by provinces, so it's hugely consequential whether or not they make the appropriate investments. You're absolutely right in that.
One thing I would point to is the agreements that we signed with provinces. For the first time, there were conditions. There were tailored bilateral agreements. There were common indicators.
CIHI just had its baseline data. When it comes out next year, we're actually going to be able to see in data rather than in anecdote which provinces are making the advances and which ones are not.
It's very interesting. In Manitoba, Nova Scotia and B.C., these elections turned on health care. People care deeply about this, so I think there's certainly a major electoral consequence to it.
We have used the Canada Health Act in many different instances to charge provinces when they're charging private fees, but this is a major topic. We have a health ministers' meeting coming up, and I would rather get there through collaboration. Obviously, that's the preferred goal.
I've had a very good conversation, as an example, with Jane Philpott in Ontario around the work she's doing in primary care. Michelle Thompson, whom I was talking to and sharing messages with, has some great ideas, in a Conservative jurisdiction, on how they can improve their health system.
There's no reason for this to be.... Just because a government is Conservative, it doesn't need to take the federal Conservative position of making cuts and attacking the health system. There's a way that we can work together collaboratively, and I think that's what we should do.
:
Thank you very much, Chair.
Welcome, Minister, and our officials as well. We shall be speaking with you soon.
I want to start on the theme of research. I think Dr. Hanley was talking about research.
I know, in my role as your Parliamentary secretary, that I've had the chance to meet with some incredible stakeholder groups that have have been advocating that we invest more in research funding. Budget 2024 really delivered in that respect.
In particular, I want to talk about brain research. In the supplements, there's $10 million in funding for the Canadian brain research fund to advance knowledge on the brain, brain diseases and brain disorders and to accelerate discoveries for improving the health and quality of life of Canadians affected by brain disease.
In your view, why is this funding into this research area critical?
Before you answer, I also want to put on record that our colleague , who brought in Bill , sought unanimous consent in the House so that it could pass, but it was denied UC by the Conservatives, which was rather partisan, because we heard clearly from so many witnesses about the need for a brain research framework in Canada, which we're looking forward to working with once it passes into law.
While we're moving ahead with this research funding, why is it so critical to support brain research in Canada and globally?
:
Thank you very much, Mr. Naqvi. I think that you're absolutely right: It was unfortunate that it was voted against.
The support for brain research is absolutely critical for a wide array of neurological conditions. When you meet patients, one of the hardest things.... Meeting patients who know that research is so close to giving them the answers to get back their lives and to be lifted out of the pain they're in or the condition they may have are the types of things that stay with you afterwards, long into the night, and they so desperately want us to make these investments. I would suggest that it's an area where we really could put down the partisan swords.
I think I mentioned another one, which is Bill , on the interoperability of data. Again, I'm not aware of any opposition to these things, and yet they're not supported because there seems to be a view that being against everything is the job of an official opposition. I just don't agree with that.
I did spend two terms in opposition, where you try to advocate in favour of solutions and ideas, and I think that Parliament, in this minority government, got a ton done, and yes, on research. We are in a time of miracles, and we need to press just a little further so that the people who are afflicted with diseases and conditions can be elevated and live their best lives.
It's a roll of the dice. It could happen to any one of us. I think all of us would hope that if one of the people we loved or we ourselves had a condition visited upon us, we had a country that was doing everything it could to find solutions and invest in the science, the data and the evidence to find answers.
:
Let's talk about seniors first. When we were announcing the one million mark—one million people connected to care—a gentleman who was at the clinic where we were came up to me. He said, “You know, a lot of years ago I had to get a tooth pulled, and it cost $700, and do you know what? I didn't go back. When I had problems in my mouth, I was terrified to walk in. I knew I couldn't afford it. I was afraid to get care.” He said, “Now I'm getting care again. I'm not afraid to go to the dentist.”
This is what this is about: people being connected to the care that they need, not having to be afraid that they're not going to be able to afford it and not being terrified, when they get a pain in their mouth, of whether or not it's going to lead to some devastating outcome that they can't afford and they have to wait to be in an emergency room to get it fixed.
I hear stories from seniors. When I was talking to a mobile smile clinic in Windsor, Navjeet was telling me about seniors setting up their family photographs once they got their dentures in, and how it's transforming their life and the joy that it gave them. You know, we're all going to exit this earth, and we're certainly going to exit this Parliament, but those stories will stay with me for the rest of my life. Connecting people to that care everywhere is absolutely critical, and we have a lot more people to connect. We're going to get there. We're going to do it as fast as we can.
:
Thank you, Minister. Thank you for staying longer than was scheduled.
That brings us to the end of this round of questions. You're welcome to stay, but you're free to leave.
Colleagues, I don't propose to suspend the meeting. We have a budget for the supplementary estimates that I would like your approval of. While we're approving that budget, perhaps we could have the other officials take up their places.
There have been some discussions among the parties. Some MPs are going to be racing for the airport soon, so I would propose that when we get the officials back up, we have even turns for the four parties of, say, four to five minutes. That will allow for adjournment at about 5:30, which will allow some of us to catch our flights.
Is everyone comfortable with that? If not, we'll go through the normal rounds of questions and entertain a motion for adjournment in the normal course.
I see some thumbs up around the table.
Thank you very much, Mr. Minister. We very much appreciate you being here, as always.
A budget has been circulated to you, colleagues, in the amount of $1,000. That will cover this meeting and the next—this one with Minister Holland and the other one with . I would ask for approval of that budget, so that you get to have a sandwich or something.
Is it the will of the committee to adopt the budget as presented?
Some hon. members: Agreed.
The Chair: I see no objections and a few thumbs up. The budget is therefore adopted.
We're going to do a sound check for Dr. Powlowski and then we'll start with rounds of questions.
:
That makes it easy. Thank you, Dr. Powlowski.
Okay, I have 5:10, so I'm going to propose questions of five minutes in length.
We have a couple of additional officials with us. I'll simply introduce them and then we'll open it up for questions.
Joining the meeting at this point, from the Department of Health, we have Jocelyne Voisin, assistant deputy minister of the health policy branch, and Dr. Celia Lourenco, associate assistant deputy minister, health products and food branch.
From the Public Health Agency of Canada, we have Martin Krumins, vice-president and chief financial officer.
Welcome to the newcomers. Thanks to the rest of you for staying here.
We're going to begin now with rounds of questions, starting with Dr. Ellis, I believe, for five minutes.
:
Thanks very much, Chair, and thanks to the officials for being here.
The nature of my questions today will be on the topic of lapsed funding, if that's helpful to all of you.
Mr. Costen, from the reading that we've been doing, it appears that at Health Canada, almost 35% of total funding ends up in lapsed funding. My understanding is that lapsed funding, of course, is not spent on programming.
Could you explain to the committee where that lapsed funding goes when it's not used—back into general revenues, perhaps—and which programs exactly are affected by lapsed funding?
Ms. Jeffrey, I would ask you the same question.
Under the Public Health Agency of Canada, it would appear that there is lapsed funding in the years that we're able to look at. I obviously don't have this year's figures, but perhaps 47% of the funding of PHAC ended up as lapsed funding.
My question to you is similar to the one for Mr. Costen. Could you confirm this number, which is considerably high, in my opinion?
If you're not able to do so now, could you please table with the committee the exact programs that have been affected over the last two years with lapsed funding?
:
Thanks very much, Ms. Jeffrey.
Could you undertake to provide the committee with a list of the items that are in the stockpile and the amounts? I think that would be important for Canadians to know. For instance, are there N95 masks, cots and blankets? What are the numbers? That would be important for Canadians to know, so, as I said, if you could undertake to provide that to the committee, I think that would make sense.
We've come back previously to this promise from the NDP-Liberal government on the Canada mental health transfer.
Mr. Costen, if I recall correctly, back when I came here in 2021, the amount was $4.5 billion. Can you tell Canadians how much of that $4.5 billion has been allocated to mental health care?
:
I certainly can provide a bit of precision on some of the figures that I believe Minister Holland noted in his commentary.
To date, we have over 23,000—to be exact, 23,010—providers who have made at least one claim. Based on our estimates, that accounts for about 93.5% of all eligible providers.
In terms of a commentary with regard to how the transition has gone, I think that there was a very good discussion earlier about the latest phase. There we've encountered some difficulties with respect to pre-authorization, and we're working through those on a priority basis.
Prior to that, I think we were feeling reasonably good about the manner in which the program has been stood up and implemented and services have been provided. There's been active outreach to providers, including to those who work in their offices and frankly have to do a lot of the hard work with respect to administering and filing forms, which is where the rubber meets the road with respect to the application of the program. I think that has paid off.
We're all very aware that at the outset, there was a lot of nervousness and concern that the administrative process would be overwhelming and difficult. Over time, through engagement and other types of very dedicated undertakings, we've managed to work through that quite successfully, and we remain confident that as we continue to implement it through phases, while there may be some bumps in the road, as they say, we will certainly endeavour to continue to make the transition as successful as it can be.
:
Thank you very much, Mr. Chair.
It is important to recall for the committee the incredibly dismal record during the Harper reign, when Harper Conservatives refused to ever provide any document of any sort and were covering up their scandals, which was a myriad of billions of dollars misspent. Again, it's a bit strange. When the Conservatives were in power, they were terrible, awful, abysmal, and we never got to the heart of anything. I'm glad that, because it's a minority Parliament, we're able to get to the bottom of things that are important and are in the public interest. We can never go back to the horrible days of the Harper regime.
I want to come back to the questions that I asked, and I thank our witnesses for being here.
I asked the minister about the issue around response time for pre-approval, but it's more properly a question to officials. Do you have that information? Again, this program has been wildly successful everywhere, particularly in Quebec, and right across the country. It's important to know how we can make the program even better.